CSIMarket Company Name, Ticker, Suppliers, else..
 
Histogen Inc   (HSTO)
Other Ticker:  
 
 
Price: $0.2150 $0.00 0.000%
Day's High: $0.215 Week Perf: 2.38 %
Day's Low: $ 0.22 30 Day Perf: -1.15 %
Volume (M): 0 52 Wk High: $ 0.30
Volume (M$): $ 0 52 Wk Avg: $0.22
Open: $0.22 52 Wk Low: $0.19



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 4
 Employees 16
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -12
 Cash Flow (TTM) (Millions $) -10
 Capital Exp. (TTM) (Millions $) 0

Histogen Inc
Histogen Inc is a biotechnology company that specializes in regenerative medicine and tissue engineering. The company develops and commercializes therapies for various medical conditions by harnessing the power of stem cells and other regenerative factors. Histogen's proprietary technology platform, called Hair Stimulating Complex (HSC), has been primarily used for developing hair growth treatments. The company's products aim to stimulate the body's natural regenerative processes to promote hair growth and improve skin health. Histogen Inc was founded in 2007 and is headquartered in San Diego, California.


   Company Address: 10655 Sorrento Valley Road San Diego 92121 CA
   Company Phone Number: 526-3100   Stock Exchange / Ticker: HSTO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AIMD      % 
ARDX   -2.96%    
DRRX        2.61% 
HOOK   -8.1%    
MRUS   -5.06%    
TSVT        0.2% 
• View Complete Report
   



Histogen Inc

Histogen Inc Shakes Off Lackluster Q3 Revenue, Unveiling Exciting Developments for 2024



Histogen Inc, a renowned biotechnology company, has experienced a significant decline in its shares over the past three months, dropping by a staggering 56%. However, while the company's shares are currently trading 10% above its 52-week low, the financial results for the third quarter of the 2023 earnings season paint a gloomy picture. This article will analyze these results and discuss their potential impact on Histogen Inc's future prospects.
Disappointing Decrease in Net Loss:
During the third quarter of the 2023 earnings season, Histogen Inc reported a net loss of $-0.90 per share, slightly less than the $-1.01 loss incurred during the same period the previous year. This reduction in net loss could be seen as a positive sign, albeit small, suggesting potential cost-cutting measures or improved operational efficiency. However, it is crucial to address the fact that the company's net deficit also increased from $-0.49 per share in the previous reporting season, which raises concerns about long-term profitability.
Histogen Inc

Histogen Inc Reports Stable Revenue for Q2 2023, Shows Positive Momentum with Decreased Losses per Share



Histogen Inc, a leading biotechnology company, recently released its financial results for the second quarter of the 2023 earnings season. The company's performance exhibited positive changes compared to the previous year and the preceding quarter. Despite challenges faced by the industry, Histogen Inc reported a decrease in losses per share and a stable revenue. This article will outline the key facts from the financial results and put them into context with the company's recent stock performance.
Financial Results:
1. Earnings per Share (EPS):
Histogen Inc recorded a significant improvement in its earnings per share for the second quarter of 2023. The company reduced its loss per share from $-1.55 per share in the same quarter a year ago to $-0.49 per share. This indicates a positive trend towards profitability.
Histogen Inc

Drastic net loss, declining revenue, and plummeting ROI position Histogen Inc. on shaky ground in the healthcare industry

Histogen Inc's recent financial report has caused investors to take notice. The company recorded a cumulative net loss of $-13 million during 12 months ending in the first quarter of 2023, resulting in a negative return on investment (ROI) of -77.72%. The healthcare sector alone saw 517 other companies achieve a higher return on investment.
The disastrous financial performance is concerning, with revenue fading by -99.867% to $0.01 million and net loss per share extended to $-0.81 from the corresponding quarter a year ago. The net loss per share has also worsened compared to the previous quarter. All of this has caused Histogen Inc's total ranking in return on investment to deteriorate from 0 to 3106, compared to the fourth quarter of 2022.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com